This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Newsletter Archive
Men's Health Weekly
Uroalerts Men's Health Weekly
April 28, 2026
Videos
Peer-to-Peer Clinical Conversations
Platelet-Rich Therapies for Erectile Dysfunction: A Systematic Review and Meta-Analysis Investigates Efficacy - Helen Bernie
Helen Bernie
Helen Bernie presents a systematic review and meta-analysis of platelet-rich therapies for erectile dysfunction.
View
Patient Selection for Penile Implant Surgery - Tobias Köhler
Tobias Köhler
Tobias Köhler shares practical strategies for optimizing penile implant outcomes.
View
Beyond the Abstracts
The Role of the Tumor Microenvironment in Penile Carcinoma and Emerging Therapeutic Concepts: A Review - Beyond the Abstract
Can Novel Biomarkers Augment Traditional Surveillance Paradigms in Early-Stage Testicular Germ Cell Tumors? a Case Study in Pre-Clinical Relapse Detection Using a Combination Micro-RNA-371a-3p and 372-3p Assay - Beyond the Abstract
Articles
Editor Selected Abstracts and Commentaries
Androgen Deficiency
Oncosexology: A Narrative Review on Sexual Health and Quality of Life in Cancer Patients.
Male Infertility
Fertility Preservation Needs of Men Undergoing Cancer Treatment: An Explorative Qualitative Study.
Measurement of Serum Zinc Levels Following the Use of Oral Medications and Supplements and Their Effects on Semen Characteristics in Male Infertility Patients.
Evaluating Sperm DNA Damage: When and Why It Does Not Add to the Evaluation of Male Factor Infertility.
Evaluating Sperm DNA Damage: When and Why It Adds to the Management of the Infertile Man.
Prostatitis
Serum Untargeted Metabolomics Integrated with SHAP-Based Machine Learning for Multiclass Stratification of Prostate Cancer, Prostatitis, and Benign Prostatic Hyperplasia.
Erectile Dysfunction
Artificial Intelligence in Patient Education: ChatGPT for Penile Prosthesis Surgery Counseling, a Likert Scale Analysis.
Erectile dysfunction and Peyronie's disease: from biologics to nanomedicine-enabled therapies.
BPH - Benign Prostatic Enlargement
Body Mass Index Lacks Predictive Influence on Perioperative, Short-Term Follow-Up, and Patient-Reported Outcomes from Holmium Laser Enucleation of the Prostate.
The Risk of Benign Prostatic Hyperplasia and Prostate Cancer With Long-Term, Low Dose Finasteride Use in Adult Men with Nonscarring Alopecia: A Propensity-Matched Observational Study.
Pharmacology, efficacy and safety of different extracts of Serenoa repens in patients with lower urinary tract symptoms and benign prostatic hyperplasia: a narrative review.
Ejaculation-sparing GreenLight anatomical PVP versus REZŪM for benign prostatic obstruction surgery with an ejaculation-sparing purpose: what are the early differences?
Penile & Urethral Cancers
Assessing the density of lymph node metastasis in various inguinal regions of penile cancer using the nine-section method: A prospective study.
Early Perioperative Morbidity After Sentinel Lymph-Node Excision and Subsequent Completion Inguinal Lymph-Node Dissection in cN0 Penile Cancer.
Testicular Cancer
Post-treatment paternity in testicular cancer survivors: Do demographic variables matter?
Presentation, management, and outcomes of testicular germ cell tumors by age.
Uncovering novel germline variants associated with testicular germ cell tumors by exome sequencing.
Primary extragonadal germ cell tumours: Real-world data from a high-volume centre.
Prostate Cancer
Post-diagnostic Inflammatory and Insulinemic Diet and Lifestyle Patterns and Risk of Prostate Cancer-Specific Mortality in the Health Professionals Follow-up Study.
Omitting Elective Pelvic Nodes Irradiation in High Risk Prostate Cancer: Report on 43 Consecutive Elderly Patients.
The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review.
Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United States.
Canagliflozin Is a Novel Androgen Receptor Pathway Inhibitor for Castrate-Sensitive and Castrate-Resistant Prostate Cancer.
Real-life PI-RADS score and biochemical recurrence after local treatment of prostate cancer in Afro-Caribbean men.
Biophysical membrane responses of hypoxic prostate cancer cells depend on kindlin-2.
Combined radiomics, PI-RADS, and clinical model improve significant prostate cancer prediction and guide biopsy decision.
PRIMA: randomized prospective multicenter non-inferiority study for primary diagnosis of clinically significant PRostate cancer by PSA and MR IMAging-study protocol for a randomized diagnostic accuracy trial.
Polygenic risk score and 20-year prostate cancer-specific mortality and survival.
Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.
Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).
Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer.
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients.
Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials.
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies.
Prognostic Value of [18F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer.
PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.
TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.
Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study.
Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial.
ProHealth: a co-designed online home-based healthy eating and exercise programme for men with prostate cancer treated with androgen deprivation therapy - a study protocol for a feasibility and preliminary efficacy randomised controlled trial.
Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients.
B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups.
Disparities in Access to Severe Incontinence Surgical Treatment with Artificial Urinary Sphincter after Radical Prostatectomy in France: A Nationwide Nested Case-control Study.
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202.
Finding Holes: Pathologist-Level Performance Using AI for Cribriform Morphology Detection in Prostate Cancer.
Trends and Patterns in Prostate Cancer Diagnostics During the Era of MRI Implementation - Real-world Evidence From a Population-based Study in the Stockholm Region, Sweden 2010-2023.
Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer.
The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease.
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer - Beyond the Abstract
CONNECT WITH US
Questions or Comments? Email us at
editors@urotoday.com
Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523
You are receiving this email because you have chosen to receive emails from UroToday.
Add us to your address book
View this email as a web page
Forward to a colleague
Manage your subscriptions
Unsubscribe
Copyright ©2026 Digital Science Press, LLC
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free